Imugene Investor Relations Material

Imugene Limited is an Australian biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered around activating the immune system to target and eliminate cancer cells, utilizing a range of technologies, including oncolytic viruses and B-cell activating immunotherapies. Imugene’s clinical pipeline includes treatments for various cancer types, and the company works on advancing its therapies through preclinical and clinical development stages. The company is headquartered in Sydney, Australia, and its shares are listed on the ASX.